What Physicians Need Now: Relevance, Timing and Trust

Sarah Heming
VP of Strategic Marketing at Diaceutics
Brand Strategy

Physicians today are navigating one of the most complex and high-pressure environments in healthcare history. With more therapies available than ever before, and a growing volume of clinical data to interpret, the challenge has gone from access to clarity.

In theory, the tools and information needed to make informed treatment decisions are readily available. In practice, however, physicians are often overwhelmed by fragmented data, delayed communications, and limited time to engage with educational content. The result? Missed opportunities to deliver optimal care.

This disconnect is reflected in recent industry data. According to a 2025 survey by the Digital Health Coalition, only 7% of pharma marketers expressed confidence in their ability to drive prescribing behavior through digital engagement, suggesting a significant gap between content delivery and clinical action (Digital Health Coalition, 2025).

 

The Reality of Modern Clinical Decision-Making

The traditional model of medical engagement is no longer fit for purpose. According to recent data:

  • 60% of healthcare professionals now restrict access to sales representatives or clinical leads
  • It takes 12-20 touchpoints to get a specialty medicine to a patient
  • Physicians are expected to stay current on rapidly evolving biomarker science, often without structured support

This environment creates a disconnect between clinical insights and action. Physicians need more than information, they need the right information, delivered at the right time, from sources they trust.

 

This challenge is compounded by the fact that many commercial teams are still adapting to a new way of working. As one Gunjan Aggarwal shared in our recent webinar:

“The biggest challenge isn’t the technology, it’s actually the transformation. We’re asking organisations to shift from the old way legacy way of working to the very new way of working.”

 

play

Many commercial teams are still adapting to a new way of working, as Gunjan Aggarwal shared in our recent webinar.

This shift highlights the importance of delivering insights that are not only innovative but also credible and actionable, especially in a highly regulated environment like healthcare.

 

What Matters Most to Physicians

To truly support physicians in making confident, timely decisions, three things are essential:

  • Relevance: Content must be clinically meaningful and aligned to the physician’s patient population. Generic messaging isn’t enough to cut through.
  • Timing: Information must be delivered at the moment of decision, not days or weeks later when the opportunity to act has passed.
  • Trust: Physicians want insights from trusted peers and experts, they don’t want promotional materials or sales-driven messaging.

 

A Smarter Way to Engage

DXRX Physician Engage was designed to address these needs directly, delivering expert-curated, clinically relevant content within 24 hours of a positive test result. By aligning with the physician’s workflow and decision-making moments, it ensures that information is not only timely, but trusted and actionable.

 

Recent campaigns have shown the power of this approach:

  • 36.3% open rates - well above industry benchmarks
  • 19.7% click-through rates - indicating strong engagement
  • 55% of HCPs ordered a novel test for the first time after engagement
  • *Data insights sourced from Diaceutics’ client projects

 

Physician Engage is part of a broader ecosystem that includes DXRX Signal, which alerts clinicians in real time when actionable results are available, and DXRX Expert Exchange, which then connects them with expert pathologists within 48 hours for peer-to-peer guidance. Together, these tools ensure that insights don’t just sit in a report, they lead to action.

 

What This Means for Physicians and Patients

In a world where attention is scarce and decisions are complex, the brands and solutions that succeed will be those that support physicians with timely, trusted, and clinically relevant information. When physicians are empowered with the right tools and insights, patients benefit and that is the ultimate goal.

Talk to Our Experts

If you're looking to improve engagement, drive prescribing behavior, and ensure patients receive the care they deserve, talk to our experts today.

Why is diagnosis often delayed for immune-mediated inflammatory diseases (IMIDs)?

Diagnosis of IMIDs, such as rheumatoid arthritis, lupus and inflammatory bowel disease, is often delayed by up to 3 months due to a combination of factors: variable clinical and imaging presentations, insufficient primary care physician knowledge, lack of specific testing, and limited access to diagnostic facilities and specialists.

Why do many IMID patients not respond to biologic treatment?

Between 30% and 40% of IMID patients do not respond to biologic disease-modifying drugs (DMDs), often due to alternative inflammatory pathways not targeted by the specific therapy, the development of neutralizing antidrug antibodies, or individual pharmacodynamic and pharmacokinetic differences.

What is the "trial and error" treatment approach in IMIDs and why is it a problem?

Many IMID patients are treated using a conventional trial-and-error approach, starting with broad options like NSAIDs or corticosteroids before moving to biologics such as TNF inhibitors, without prior molecular testing. This fail-first approach means many patients experience prolonged periods of ineffective treatment, increased tissue damage, and worse long-term outcomes.

What is PrismRA and how does it improve rheumatoid arthritis treatment decisions?

PrismRA is an AI-assisted predictive molecular signature test that received Medicare local coverage determination in September 2023 to help guide TNF inhibitor treatment decisions in rheumatoid arthritis patients. It has been shown to be three times more accurate in predicting remission for patients receiving PrismRA-guided therapy selection compared to standard approaches.

What are the biggest barriers to precision medicine in IMIDs?

Key barriers include a lack of disease-specific biomarkers for early detection and treatment response prediction, delayed patient access to specialist care, complex and overlapping disease phenotypes, and treatment developers focusing on molecular targets rather than individual patient needs. Addressing these barriers requires earlier collaboration between diagnostic and pharmaceutical partners.

How can pharma and diagnostic companies improve precision medicine outcomes for IMID patients?
Diaceutics recommends pharma companies incorporate testing directly into clinical trial design, adopt a patient-centered precision medicine approach rather than a purely molecular-target focus, and establish early Rx-Dx partnerships. Diagnostics providers should also continue developing patient stratification tools to identify which patients will benefit most from specific treatments.
Written By Sarah Heming
Sarah Heming is Interim VP of Strategic Marketing at Diaceutics, where she leads brand strategy and global marketing to help pharma and biotech partners bring diagnostic-driven therapies to more eligible patients. A senior marketing and communications leader with more than two decades across Fortune 500 and highly regulated industries, she has driven transformative growth, award-winning product launches and high-impact corporate rebrands. Sarah previously held marketing leadership roles at Zoetis, Mölnlycke Health Care and Abbott, bringing deep expertise in brand building, stakeholder engagement and omnichannel strategy.
Read more by this author
Share:

Newsletter sign up

Sign up to our bi-weekly newsletter covering the latest insights to optimize commercialization of diagnostic driven therapies to help empower your decisions.

READY TO DO COMMERCIALIZATION DIFFERENTLY?

Every patient journey contains opportunities to improve testing, engagement, and adoption. We can help you find them so more people get the right therapy sooner.